Sotatercept and pulmonary arterial hypertension

Pulmonary arterial hypertension is a chronic progressive disease characterized by elevated pulmonary artery pressure, ultimately leading to right heart failure and even death. The primary pathological mechanism of pulmonary arterial hypertension involves pulmonary vascular remodeling, resulting in increased pulmonary vascular resistance. Current targeted therapies for pulmonary arterial hypertension primarily function to dilate the pulmonary arteries, improve hemodynamic parameters, and enhance patients' quality of life. However, these therapies fail to fundamentally reverse pulmonary vascular remodeling or achieve a cure. Sotatercept, the world's first biological agent targeting pulmonary arterial hypertension, restores the balance between pro-proliferative and anti-proliferative signaling pathways, effectively reversing pulmonary vascular remodeling. Multiple clinical trials have demonstrated the efficacy of sotatercept in reducing pulmonary vascular resistance and pulmonary artery pressure, positioning it as one of the most promising targeted therapies for pulmonary arterial hypertension in the future.